Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

Upadacitinib improved multiple immune-related conditions in one patient.

Pimecrolimus cream is not effective for treating alopecia areata.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

A new mix of anthralin and calcipotriene might help treat severe hair loss.

Injecting endometrial cells and PRP can improve pregnancy chances in ART.

The analysis aims to identify the most effective and safest treatments for alopecia areata.

JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.

Baricitinib may effectively treat oral lichen planus.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

Oral Apremilast effectively treats alopecia areata in most patients.

Tofacitinib helped regrow hair in most patients with severe hair loss.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

Combining PRP with hydroquinone is more effective for treating melasma than using hydroquinone alone.

Baricitinib significantly regrows hair in teens with severe alopecia areata.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.

Mycophenolate mofetil can effectively treat autoimmune hepatitis when standard drugs fail.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Hidradenitis Suppurativa is a chronic skin condition best treated early with surgery for better outcomes and less recurrence.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

Baricitinib is effective and safe for treating severe alopecia areata.

A woman with skin and joint issues progressed from one type of lupus to another, highlighting the need to recognize complex conditions.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.